共 31 条
Selective internal radiation therapy for liver malignancies
被引:11
作者:
Moir, J. A. G.
[1
]
Burns, J.
[1
]
Barnes, J.
[1
]
Colgan, F.
[2
]
White, S. A.
[1
]
Littler, P.
[2
]
Manas, D. M.
[1
]
French, J. J.
[1
]
机构:
[1] Freeman Rd Hosp, Dept Hepatopancreatobiliary & Transplant Surg, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England
[2] Freeman Rd Hosp, Dept Intervent Radiol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England
关键词:
HEPATOCELLULAR-CARCINOMA;
Y-90;
MICROSPHERES;
COLORECTAL-CANCER;
METASTASES;
RADIOEMBOLIZATION;
CHEMOTHERAPY;
RESECTION;
MANAGEMENT;
SURVIVAL;
TRIAL;
D O I:
10.1002/bjs.9924
中图分类号:
R61 [外科手术学];
学科分类号:
摘要:
BackgroundSelective internal radiation therapy (SIRT) is a non-ablative technique for the treatment of liver primaries and metastases, with the intention of reducing tumour bulk. This study aimed to determine optimal patient selection, and elucidate its role as a downsizing modality. MethodsData were collected retrospectively on patients who underwent SIRT between 2011 and 2014. The procedure was performed percutaneously by an expert radiologist. Response was analysed in two categories, based on radiological (CT/MRI according to Response Evaluation Criteria In Solid Tumours(RECIST)) and biological (-fetoprotein, carcinoembryonic antigen, carbohydrate antigen 19-9, chromogranin A) parameters. ResultsForty-four patients were included. Liver metastases from colorectal cancer (22 patients) and hepatocellular carcinoma (HCC) (9) were the most common pathologies. Radiological response data were collected from 31 patients. A reduction in sum of diameters (SOD) was observed in patients with HCC (median -241 (95 per cent c.i. -434 to -38) per cent) and neuroendocrine tumours (-300 (-456 to -77) per cent), whereas a slight increase in SOD was seen in patients with colorectal cancer (49 (-106 to 553) per cent). Biological response was assessed in 17 patients, with a reduction in 12, a mixed response in two and no improvement in three. Six- and 12-month overall survival rates were 71 and 41 per cent respectively. There was no difference in overall survival between the RECIST response groups (median survival 375, 290 and 214 days for patients with a partial response, stable disease and progressive disease respectively; P = 0130), or according to primary pathology (P = 0063). Seven patients underwent liver resection with variable responses after SIRT. ConclusionSIRT may be used to downsize tumours and may be used as a bridge to surgery in patients with tumours deemed borderline for resection. Treatment from inside
引用
收藏
页码:1533 / 1540
页数:8
相关论文